Navigation Links
GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports
Date:8/23/2014

New York, New York (PRWEB) August 23, 2014

GranuFlo lawsuit (http://www.thegranuflolawsuit.com) filings stemming from the 2012 GranuFlo and NaturaLyte dialysis concentrate recall continue to mount in a federal multidistrict litigation underway in U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP reports. According to an updated docket report issued by the U.S. Judicial Panel on Multidistrict Litigation (JPML) on August 15th, at least 2,028 claims are pending in the proceeding. In July, the Panel reported that 1,942 GranuFlo and NaturaLyte lawsuits had been filed, indicating that 96 cases have been added to the litigation over the past month. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)

“Our Firm continues to hear from individuals who were allegedly harmed by GranuFlo and NaturaLyte. We are not surprised that this proceeding continues to grow,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now offering free and confidential GranuFlo lawsuit evaluations to individuals who allegedly suffered serious heart injuries after being administered the dialysis drugs.

GranuFlo and NaturaLyte Lawsuit Allegations:
According to court documents, all of the claims pending in the District of Massachusetts were filed on behalf of individuals who allegedly suffered catastrophic cardiovascular events, including heart attacks, strokes, and sudden cardiac death, due to the administration of GranuFlo and NaturaLyte during dialysis treatments. The lawsuits also accuse Fresenius Medical Care of failing to adequately warn dialysis patients and their doctors about the heart injuries related to the use of its products, and assert that the company continued to promote the dialysis concentrates even after becoming aware of their potential risks.

On March 29, 2012, Fresenius issued an Urgent Product Notification that warned of GranuFlo and NaturaLyte’s association with metabolic alkalosis, a condition that may be associated with serious heart problems. According to the notice, the two products contained a higher level of an ingredient the body converts to bicarbonate, and needed to be dosed differently than rival dialysis concentrates. Two months later, the U.S. Food & Drug Administration (FDA) granted the notification Class I recall status, its most urgent safety alert.

A New York Times report published in June 2012 indicates that the FDA was also investigating Fresenius Medical Care, after finding that the company knew about hundreds of patient deaths that followed use of GranuFlo and NaturaLyte.*

Individuals who allegedly suffered heart attacks, strokes, or other life-threatening heart events within 72 hours of using GranuFlo and NaturaLyte in dialysis may be entitled to compensation for their injuries. Learn more about lawsuits filed after the GranuFlo recall at Bernstein Liebhard LLP’s website, or the Firm’s Facebook page: https://www.facebook.com/granuflolawsuit. For additional information, and to arrange for a free case review, please call 800-511-5092.

*nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.thegranuflolawsuit.com
https://plus.google.com/115936073311125306742?rel=author

Read the full story at http://www.prweb.com/releases/granuflo-lawsuit/granuflo-recall/prweb12116119.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. GranuFlo Lawsuit Consolidation Supported by Fresenius Medical Care, Bernstein Liebhard LLP Reports
2. GranuFlo Recall Website Launched By Hissey Kientz, LLP Law Firm
3. d'Oliveira & Associates Releases Fresenius Infographic about the FDA Recall of NaturaLyte and GranuFlo
4. GranuFlo Lawsuits Filed in Wake of GranuFlo and NaturaLyte Recall Mount in State and Federal Courts, Bernstein Liebhard LLP Reports
5. The National Plaintiff’s Law Firm of Baron and Budd Handling Granuflo Recall Lawsuits
6. New Granuflo Cardiac Arrest Lawsuit: Now, AttorneyOne Can Provide Advice
7. GranuFlo Lawsuit News: Bernstein Liebhard LLP Reports on Growing Litigation Surrounding GranuFlo Recall
8. Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama
9. GranuFlo Lawsuits Moving Forward in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports
10. GranuFlo Lawsuits Move Forward, as Bernstein Liebhard Notes Issuance of New Order in Federal GranuFlo Recall Litigation
11. GranuFlo Lawsuit News: W.Va. Man’s Lawsuit Goes to Federal Court, Rottenstein Law Group LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... , ... May 24, 2017 , ... ... of ExtraHop to its solutions portfolio. ExtraHop delivers an analytics-first approach, layered with ... every IT system, from the datacenter to the cloud to the edge. Through ...
(Date:5/24/2017)... ... 24, 2017 , ... The CFOs included on this list ... in the nation and help their organizations navigate the challenges in healthcare today. ... in developing successful hospital and health system strategy. , Becker's Hospital Review has ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International (MDLand), a ... today that its iClinic V12.2 solution has achieved approval from National Center for ... PCMH 2017 standards which emphasize team-based care with a significant focus on the ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May ... since 2009, according to a Workers Compensation Research Institute (WCRI) study, a contrast ... North Carolina System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical ...
(Date:5/23/2017)... ... 2017 , ... London, May 23, 2017: Walter Schindler, the Founder and Managing ... Guest Speaker and Contributor to a weeklong series of classes, meetings, field trips and ... , Walter Schindler and SAIL Capital have received an increasing number ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)... -- Bayer announced today that the latest research from across ... 53 rd Annual Meeting of the American Society ... Chicago . The ... and thyroid cancers, as well as lymphomas, and includes ... of copanlisib in patients with relapsed or refractory follicular ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology: